|
Evaluation of gastric side effects of new form of deferiprone, (L1; Enteric coated) in thalassemia major patients
|
A. Azarkeivan   , M. Shaeigan , M.S. Eslami , Sh Ghazizadeh , A Oshidari , AR Narenjian |
|
|
| Keywords: Key words: Thalassemia, deferiprone, Tablets٬ Enteric-Coated |
|
|
Full-Text [PDF 211 kb]
(15835 Downloads)
| Abstract (HTML) (10882 Views)
|
Type of Study: Research |
Subject:
Hematology
Published: 2016/09/7
|
|
|
|
|
|
|
Full-Text: (20570 Views) |
References :
- Olivieri NF, Brittenham GM. Management of the thalassemias. Cold Spring Harb Perspect Med 2013; 3(6): a011767.
- Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood 2012; 120(18): 3657-69.
- Marsella M, Borgna-Pignatti C, Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Hematol Oncol Clin North Am 2014; 28(4): 703-27.
- Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Desferrioxamine mesylate for managing transfusional iron overload in people
with transfusion-dependent thalassaemia. Cochrane Database Syst Rev 2013; 8: CD004450.
- Uygun V, Kurtoglu E. Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology 2013; 18(1): 50-5.
- Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2013; 8: CD004839.
- Song TS, Hsieh YW, Peng CT, Chen TL, Lee HZ, Chung JG, et al. Combined versus monotherapy or concurrent therapy for treatment of thalassaemia. In Vivo 2014; 28(4): 645-9.
- Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013; 128(3): 281-308.
- Danjou F, Origa R, Anni F, Saba L, Cossa S, Podda G, et al. Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment . Blood Cells Mol Dis 2013; 51(3): 142-5.
- Kuo KH, Mrkobrada M. A Systematic Review and Meta-Analysis of Deferiprone Monotherapy and in Combination with Deferoxamine for Reduction of Iron Overload in Chronically Transfused Patients. Hemoglobin 2014; 38(6): 409-12.
- Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, et al. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin 2014; 38(5): 345-50.
- Makis A, Chaliasos N, Alfantaki S, Karagouni P, Siamopoulou A. Chelation therapy with oral solution of deferiprone in transfusional iron-overloaded children with hemoglobinopathies. Anemia 2013; 2013: 121762.
- Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatr Clin North Am 2013; 60(6): 1393-406.
- Jamuar SS, Lai AH, Tan AM, Chan MY, Tan ES, Ng IS. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia. J Paediatr Child Health 2011; 47(11): 812-7.
- Jamuar SS, Lai AH. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol 2012; 3(5): 299-307.
- Smith GC, Alpendurada F, Carpenter JP, Alam MH,
Berdoukas V, Karagiorga M, et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson 2011; 13: 34.
- Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson 2013; 15: 38.
- Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatr Clin North Am 2013; 60(6): 1393-406.
- Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2013; 8: CD004839.
- Karami H, Kosaryan M, Abolghasemi H, Rashidighader F, Vahidshahi K, Dabirian M, et al. Deferiprone plus deferoxamine versus deferoxamine iron chalation in beta thalassemia major. Sci J Iran Blood Transfus Organ 2011; 7(4): 227-34. [Article in Farsi]
- Eshghi P. Complications of combined treatment with deferiprone and desferrioxamine in thalassemic patients. Iran J Med Sci 2007; 32(1): 40-4.
- Hashemieh M, Khosravi Sh .Determining the efficacy of Deferiprone (L1) on decreasing ferritin levels of Thalassemia patients in Arak city. Journal Of Arak Medical University 2008; 11(1): 109-16. [Article in Farsi]
- Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. Transfusion 2014; 54(3): 646-9.
|
Sci J Iran Blood Transfus Organ 2016; 13(3): 163-169
|
Evaluation of gastric side effects of new form
of deferiprone, (L1; Enteric coated) in thalassemia
major patients
Azarkeivan A.1,2, Shaiegan M.1, Eslami M.1,2, Ghazizadeh Sh.1,2, Oshidari A.1,2, Narenjian A.R.1,2
1Blood Transfusion Research center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Adult Thalassemia Clinic, Tehran, Iran
Abstract
Background and Objectives
An important consequence of chronic blood transfusion in thalassemia is iron overload with treatment of iron chealation drugs. One of these drugs is deferiprone (L1) which is usually used as the combination therapy with desferoxamin especially in patients with iron overload. Nausea and vomiting is the common side effects of L1 which sometimes gets so bad that the patient can not tolerate the drug. We tried Enteric coated; EC with the aim of decreasing the gastric side effects.
Materials and Methods
We started enteric coated for 100 patients and followed them for gastric side effects for six months. All of them could not tolerate the previous form of L1 because of severe nausea and vomiting.
Results
Two of our patients moved to other cities and could not be followed by this therapy; 98 patients were studied: 91 thalassemia major and 7 intermedia, 39 male, 59 female with the mean age of 25.16 + 6.03. Out of the total number, 67 (68.4%) patients were on the combination therapy because of high ferritin level and 31 (31.6%) had cardiac iron overload and high ferritin level. Four patients could not continue the treatment, 3 because of the recurrence of nausea and vomiting and 1 because of artheralgia; however, 94 (96%) could tolerate the EC form and successfully continued the treatment.
Conclusions
The enteric form of L1 had good results on GI side effects reduction so that 96% of patients could tolerate the medication and continue the treatment without any nausea and vomiting.
Key words: Thalassemia, deferiprone, Tablets ٬ Enteric-Coated
Received: 9 Jun 2015
Accepted:25 May 2016
Correspondence: Azarkeivan A., MD. Pediatrics Hematologist-Oncologist. Associate Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine and Adult Thalassemia Clinic.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 88074135; Fax: (+9821) 22087853
E-mail: azazarkeivan@yahoo.com
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Azarkeivan A, Shaeigan M, Eslami M, Ghazizadeh S, Oshidari A, Narenjian A. Evaluation of gastric side effects of new form of deferiprone, (L1; Enteric coated) in thalassemia major patients. Sci J Iran Blood Transfus Organ 2016; 13 (3) :163-169 URL: http://bloodjournal.ir/article-1-868-en.html
|
.jpg)
.png)
